Usefulness of troglitazone administration to obese hyperglycaemic patients with near‐normoglycaemia

Sekino, Nori; Kashiwabara, Akiko; Inoue, Takato; Kawasaki, Terukazu; Ogata, Nobuyuki; Sawashige, K.; Yamanouchi, Toshikazu

doi:10.1046/j.1463-1326.2003.00248.x

Cited by 7 publications

(3 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thiazolidinediones (TZDs), a class of oral antidiabetic agents, have been shown to improve insulin sensitivity in a range of insulin‐resistant states, including obesity and IGT [11–14]. Both rosiglitazone and pioglitazone have been found to significantly decrease fasting plasma glucose and glycosylated haemoglobin (HbA 1c ) levels in patients with diabetes [15].…”

Section: Introductionmentioning

confidence: 99%

Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance

Durbin

2004

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

Aim: The second-generation thiazolidinediones (TZDs), rosiglitazone and pioglitazone, significantly decrease fasting plasma glucose and glycosylated haemoglobin (HbA 1c ) levels in patients with diabetes. Recent studies suggest that early treatment with TZDs may prevent the progression from insulin resistance (IR) to type 2 diabetes mellitus (T2DM). This prospective analysis examined the effect of early TZD treatment in the prevention or delay of T2DM in a multiethnic population with impaired glucose tolerance (IGT) and IR. Methods: The analysis included 172 patients (aged 29-86 years) with IGT and IR (normal or borderline HbA 1c , C-peptide levels > 2 mg/ml, fasting blood sugar 100-125 mg/dl, and 2-h postprandial blood glucose levels 140-200 mg/dl). Patients in the active treatment group (n ¼ 101) had received troglitazone for an average of 10 months before being randomly switched to rosiglitazone (4 mg/day) or pioglitazone (30 mg/day). Patients were switched when troglitazone was withdrawn from the US market because of liver toxicity concerns. Patients with IGT and IR who received no antidiabetic medication served as a control group (n ¼ 71). HbA 1c and C-peptide levels were measured at baseline (2 years) and study end point (3 years). Kaplan-Meier testing, using time to outcome as the main outcome variable, determined risk reduction in the TZD group relative to the control group. Results: Mean HbA 1c and C-peptide levels decreased for patients receiving either TZD at the 2-year assessment, and reductions were maintained at study end point. After 2 years, none of the patients receiving TZD therapy progressed to T2DM; three patients progressed to T2DM by study end point. In the control group, 11 patients became diabetic after 2 years and 19 patients became diabetic by the end of the study. The incidence (risk reduction) of diabetes after 3 years was 88.9% lower in the TZD group compared with the control group (p < 0.001). Conclusions: The TZDs, rosiglitazone and pioglitazone, were effective in reducing HbA 1c and C-peptide levels in patients with IGT/IR. Progression of IR/IGT to T2DM appears to be significantly delayed or prevented with early TZD treatment.

show abstract

Section: Introductionmentioning

confidence: 99%

Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance

Durbin

2004

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

show abstract

“…In patients with insulin resistance, such as obese hyperglycemic patients and patients on steroid treatment, the usefulness of glitazone has been demonstrated in several studies [7,14]. In addition, the combination of glargine insulin with oral antidiabetic drugs significantly lowers insulin doses and achieves better blood glucose levels [15]. In severe cases of overweight with insulin resistance, surgical interventions may be a method of choice [16].…”

Section: Discussionmentioning

confidence: 99%

Improvement of glycemic control after a 3–5 day insulin infusion in type 2-diabetic patients with insulin resistance can be maintained with glitazone therapy

Biesenbach

Grafinger

Raml

2006

Wien Klin Wochenschr

View full text Add to dashboard Cite

Short-term insulin infusion therapy is effective in improving metabolic control and, concomitantly, in reducing insulin requirement in poorly insulin-treated type 2-diabetic patients; however, these effects are mostly limited to three months. With additional glitazone treatment after the insulin infusion, the improvement in metabolic control and the reduced insulin requirement can be maintained for more than six months.

show abstract

“…The overall risk that patients with IGT will develop diabetes is 3-9% per year in the United States (Ipp 2000). TZDs improve insulin sensitivity in a range of insulin-resistant states without diabetes, including obesity and IGT (Ghanim et al 2001;Sekino et al 2003;Bennett et al 2004).…”

Section: Use In Diabetes Preventionmentioning

confidence: 99%

Peroxisome proliferator-activated receptor-γ agonists and diabetes: Current evidence and future perspectives

Chiarelli

Marzio²

2008

VHRM

112

View full text Add to dashboard Cite

Abstract:Since their initial availability in 1997, the thiazolidinediones (TZDs) have become one of the most commonly prescribed classes of medications for type 2 diabetes. In addition to glucose control, the TZDs have a number of pleiotropic effects on myriad traditional and non-traditional risk factors for diabetes. TZDs may benefi t cardiovascular parameters, such as lipids, blood pressure, infl ammatory biomarkers, endothelial function and fi brinolytic state. In this review, we summarise the experimental, preclinical and clinical data regarding the effects of the TZDs in conditions for which they are indicated and discuss their potential in the treatment of other conditions.

show abstract

Usefulness of troglitazone administration to obese hyperglycaemic patients with near‐normoglycaemia

Abstract: These findings suggest that the administration of this insulin sensitizer is useful in the treatment of obese Japanese subjects with borderline or mild diabetics accompanied by hyperinsulinaemia.

Cited by 7 publications

References 19 publications

Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance

Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance

Improvement of glycemic control after a 3–5 day insulin infusion in type 2-diabetic patients with insulin resistance can be maintained with glitazone therapy

Peroxisome proliferator-activated receptor-γ agonists and diabetes: Current evidence and future perspectives

Contact Info

Product

Resources

About

Usefulness of troglitazone administration to obese hyperglycaemic patients with near‐normoglycaemia

Abstract: These findings suggest that the administration of this insulin sensitizer is useful in the treatment of obese Japanese subjects with borderline or mild diabetics accompanied by hyperinsulinaemia.

Cited by 7 publications

References 19 publications

Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance

Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance

Improvement of glycemic control after a 3–5 day insulin infusion in type 2-diabetic patients with insulin resistance can be maintained with glitazone therapy

Peroxisome proliferator-activated receptor-&gamma; agonists and diabetes: Current evidence and future perspectives

Contact Info

Product

Resources

About

Peroxisome proliferator-activated receptor-γ agonists and diabetes: Current evidence and future perspectives